Dec. 18, 2024—Deepull announced it has received breakthrough device designation from the FDA for its UllCore bloodstream infection test. The test detects 95 percent of pathogens associated with bloodstream infections that may lead to sepsis, as well as select genetic determinants of antimicrobial resistance, and has a turnaround time of one hour. The real-time multiplex PCR system extracts and analyzes total microbial DNA from 8 mL of whole blood.